ClinicalTrials.gg
RecruitingNCT07842575Updated Sep 25, 2026

DEVELOPMENT AND VALIDATION OF THE URINARY INCONTINENCE KINESIOPHOBIA SEVERITY SCALE

An observational study in Incontinence, sponsored by Ahi Evran University Education and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Ahi Evran University Education and Research Hospital · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Sep 25, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
500
Ages
18 Years and older
Sex
Female
01

Study summary

This study aims to develop and validate a novel Turkish-language self-report instrument, the Kinesiophobia Severity Scale in Urinary Incontinence (KSS-UI), to assess movement avoidance and fear of movement associated with concerns about urinary leakage in individuals with urinary incontinence. Following scale development, its validity and reliability will be evaluated through psychometric analyses in accordance with the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) recommendations.

Read the detailed description

This methodological study aims to develop and evaluate the validity and reliability of the Kinesiophobia Severity Scale in Urinary Incontinence (KSS-UI), a novel Turkish-language self-report instrument designed to assess fear of movement and movement avoidance associated with concerns about urinary leakage.

The study will include individuals with urinary incontinence, including stress, urgency, and mixed urinary incontinence. Participants will be recruited exclusively from individuals reporting urinary incontinence among relatives of patients attending the Physical Therapy and Rehabilitation Center. Individuals who meet the eligibility criteria and voluntarily agree to participate will be enrolled in the study. Written informed consent will be obtained from all participants before data collection.

Initially, an item pool was developed through a comprehensive literature review, semi-structured interviews with 15-20 individuals with urinary incontinence, and recommendations from experts in relevant clinical disciplines. Following ethical approval, the items will undergo content validity assessment by a multidisciplinary panel of at least 10 experts. Item relevance, clarity, simplicity, and necessity will be evaluated using the Content Validity Ratio (CVR), Content Validity Index (CVI), and modified kappa statistics.

Subsequently, face validity and comprehensibility will be assessed through cognitive interviews with 8-12 individuals. Items will be revised based on participant feedback. Pilot testing will be conducted to examine item distributions, floor and ceiling effects, corrected item-total correlations, internal consistency, and item discrimination.

Following these preliminary evaluations, the revised scale will be administered to eligible participants during a single assessment session. Questionnaire completion is expected to take approximately 15-20 minutes.

Psychometric analyses will be performed to evaluate the validity and reliability of the scale. Based on the findings, the final scale will be established, and a scoring and interpretation guide will be developed.

The study is expected to provide a valid and reliable instrument for assessing urinary incontinence-related kinesiophobia and contribute to the evaluation of movement-related fear and avoidance behaviors in individuals with urinary incontinence.

02

Conditions studied

  • Incontinence

Keywords

  • Incontinence
  • Kinesiofobia
03

In context

Lead sponsor

Ahi Evran University Education and Research Hospital is the lead sponsor of 39 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adults aged 18 years or older who report urinary incontinence, including stress, urgency, and mixed urinary incontinence. Participants will be recruited from among relatives of patients attending the Physical Therapy and Rehabilitation Center. Eligible individuals who report urinary leakage at least once per week during the past three months, are able to read and understand Turkish, and voluntarily agree to participate will be included in the study. Individuals with active lower urinary tract infections or conditions that prevent independent completion of the questionnaires will be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being 18 years of age or older
  • Reporting symptoms of incontinence at least once a week for the past 3 months (ICIQ-SF score ≥ 1)
  • Having the ability to read and comprehend Turkish
  • Having been informed about the study and provided written

Exclusion criteria

Exclusion Criteria:

  • Having an active lower urinary tract infection
  • Inability to complete the scales independently due to cognitive impairment, advanced dementia, or limited literacy
  • Individuals who refuse to participate in the study or do not sign the form
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Incontinance

    This group will consist of individuals with urinary incontinence, including stress, urgency, and mixed urinary incontinence, who are recruited from among relatives of patients attending the Physical Therapy and Rehabilitation Center. Eligible participants who voluntarily agree to participate will complete the newly developed Kinesiophobia Severity Scale in Urinary Incontinence (KSS-UI) to assess fear of movement and movement avoidance associated with concerns about urinary leakage. The scale will undergo psychometric evaluation to assess its validity and reliability. No therapeutic intervention will be administered as part of the study.

06

What researchers measure

Primary outcomes

  1. Content Validity of the Kinesiophobia Severity Scale in Urinary Incontinence (KSS-UI)

    The content validity of the newly developed scale will be evaluated by a multidisciplinary panel of at least 10 experts. Item relevance, clarity, simplicity, and necessity will be assessed using the Content Validity Ratio (CVR), Item-level Content Validity Index (I-CVI), Scale-level Content Validity Index (S-CVI), and modified kappa statistics.

    Time frame: During the initial expert evaluation, before participant recruitment for the main validation study.

Secondary outcomes

  1. Internal Consistency of the KSS-UI

    The internal consistency of the KSS-UI will be evaluated using Cronbach's alpha coefficient and corrected item-total correlations. The contribution of individual items to scale reliability will also be examined.

    Time frame: Baseline (single assessment session; approximately 15-20 minutes).

  2. Item Discrimination and Item Performance of the KSS-UI

    Item performance will be evaluated by examining item distributions, floor and ceiling effects, and corrected item-total correlations. Item discrimination will be assessed by comparing item scores between the upper and lower 27% of participants based on total scale scores.

    Time frame: Baseline (single assessment session; approximately 15-20 minutes).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participants' privacy and confidentiality, given the sensitive nature of urinary incontinence-related health information. Study findings will be reported in aggregate form.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Jan 2027, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 25, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Jan 10, 2027
CompletionEst.
Feb 15, 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07842575
Lead sponsor
Ahi Evran University Education and Research Hospital
Responsible party
Esra BAYRAMOĞLU DEMİRDÖĞEN (Lecturer, Ahi Evran University Education and Research Hospital) — Principal investigator
First posted
Sep 25, 2026
Start date
Sep 1, 2026
Primary completion
Jan 10, 2027 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Esra BAYRAMOĞLU DEMİRDÖĞEN
Contact
esra.bayramoglu@ahievran.edu.tr
05426961169
Esra BAYRAMOĞLU DEMİRDÖĞEN
Contact
esra.bayramoglu@ahievran.edu.tr
5426961169
Esra BAYRAMOĞLU DEMİRDÖĞEN
principal investigator · Kırşehir Eğitim ve Araştırma Hastanesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion